{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:05:41Z","timestamp":1784225141610,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,16]]},"group-title":"In Review","reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,1]]},"abstract":"<title>Abstract<\/title>\n                <p>Human papillomavirus (HPV)-associated malignancies remain a significant global health burden, particularly among individuals with established infection or limited access to prophylactic vaccination. Although the E6 and E7 oncogenes of high-risk HPV types represent attractive therapeutic targets, current vaccine approaches have shown limited clinical efficacy. In this study, we investigated multiple strategies to enhance the therapeutic activity of an HPV16 E6\/E7 mRNA vaccine. To leverage pre-existing antiviral immune memory, we engineered an immunodominant CD4\u207a T-cell epitope derived from herpes simplex virus type 1 (HSV-1) glycoprotein D (gD) into a ubiquitin-tagged mRNA-UB-E6\/E7 construct, generating an epitope-enhanced HPV16 therapeutic vaccine. The ubiquitin moiety was incorporated as an additional potentiation strategy to enhance antigen processing and presentation. Antitumor efficacy, antigen-specific T-cell responses, and tumor immune infiltration were assessed following vaccination alone or in combination with the histone deacetylase (HDAC) inhibitor entinostat or the STING agonist ADU-S100, two immunomodulatory agents known to remodel the tumor microenvironment. Incorporation of ubiquitin and HSV-1 gD CD4\u207a T-cell epitope significantly enhanced HPV-specific CD8\u207a T-cell responses and improved antitumor efficacy. Furthermore, combination therapy with either entinostat or ADU-S100 provided additional therapeutic benefit. These findings demonstrate that incorporation of a heterologous HSV-1 gD helper epitope can augment HPV E6\/E7-targeted mRNA vaccination by harnessing pre-existing HSV-1-specific immune memory and enhancing CD4\u207a T-cell help. Together with ubiquitin-mediated enhancement of antigen presentation and modulation of the tumor microenvironment through HDAC inhibition or STING activation, these complementary potentiation strategies may further improve therapeutic outcomes and support the development of combinatorial immunotherapeutic approaches for HPV-associated cancers.<\/p>","DOI":"10.21203\/rs.3.rs-9890379\/v1","type":"posted-content","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:31:58Z","timestamp":1784223118000},"source":"Crossref","is-referenced-by-count":0,"title":["Stepwise Enhancement of HPV16 E6\/E7 mRNA Vaccine Efficacy Using HSV-1 gD Epitope Incorporation and Immune-Modulating Agents"],"prefix":"10.21203","author":[{"given":"Kyle","family":"Johnson","sequence":"first","affiliation":[{"name":"University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane Jingting","family":"Lim","sequence":"additional","affiliation":[{"name":"University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanfu","family":"Wu","sequence":"additional","affiliation":[{"name":"University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyet","family":"Tu","sequence":"additional","affiliation":[{"name":"University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun Xiaoliu","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"Martel C","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S (2017) Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141:664\u2013670. 10.1002\/ijc.30716","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. 10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano B","year":"2018","unstructured":"Serrano B, Brotons M, Bosch FX, Bruni L (2018) Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol 47:14\u201326. 10.1016\/j.bpobgyn.2017.08.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030391","author":"Cheng L","year":"2020","unstructured":"Cheng L, Wang Y, Du J (2020) Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 8. 10.3390\/vaccines8030391"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1016\/j.vaccine.2007.06.012","article-title":"Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine","volume":"25","author":"Brandsma JL","year":"2007","unstructured":"Brandsma JL, Shlyankevich M, Zelterman D, Su Y (2007) Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine 25:6158\u20136163. 10.1016\/j.vaccine.2007.06.012","journal-title":"Vaccine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/gt.2015.17","article-title":"Intravaginal HPV DNA vaccination with electroporation induces local CD8\u2009+\u2009T-cell immune responses and antitumor effects against cervicovaginal tumors","volume":"22","author":"Sun Y","year":"2015","unstructured":"Sun Y, Peng S, Qiu J, Miao J, Yang B, Jeang J, Hung CF, Wu TC (2015) Intravaginal HPV DNA vaccination with electroporation induces local CD8\u2009+\u2009T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther 22:528\u2013535. 10.1038\/gt.2015.17","journal-title":"Gene Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03224-20","author":"Peng S","year":"2021","unstructured":"Peng S, Ferrall L, Gaillard S et al (2021) Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. mBio. 12. https:\/\/doi.org\/10.1128\/mbio.03224-20"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41541-024-00894-0","article-title":"T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector","volume":"9","author":"Fert I","year":"2024","unstructured":"Fert I, Douguet L, Vesin B et al (2024) T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector. npj Vaccines 9:102. 10.1038\/s41541-024-00894-0","journal-title":"npj Vaccines"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.4110\/in.2023.23.e41","article-title":"The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer","volume":"23","author":"Topchyan P","year":"2023","unstructured":"Topchyan P, Lin S, Cui W (2023) The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer. Immune Netw 23:e41. 10.4110\/in.2023.23.e41","journal-title":"Immune Netw"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","article-title":"Requirement for CD4 T cell help in generating functional CD8 T cell memory","volume":"300","author":"Shedlock DJ","year":"2003","unstructured":"Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337\u2013339. 10.1126\/science.1082305","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.mt.6300121","article-title":"DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4\u2009+\u2009T-cell immune responses and enhances vaccine potency","volume":"15","author":"Hung CF","year":"2007","unstructured":"Hung CF, Tsai YC, He L, Wu TC (2007) DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4\u2009+\u2009T-cell immune responses and enhances vaccine potency. Mol Ther 15:1211\u20131219. 10.1038\/sj.mt.6300121","journal-title":"Mol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1090533","DOI":"10.3389\/fimmu.2023.1090533","article-title":"Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials","volume":"14","author":"McCarthy PM","year":"2023","unstructured":"McCarthy PM, Valdera FA, Smolinsky TR et al (2023) Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. Front Immunol 14:1090533. 10.3389\/fimmu.2023.1090533","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas M","year":"2025","unstructured":"Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA (2025) Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Reviews Clin Oncol 22:163\u2013181. 10.1038\/s41571-024-00984-x","journal-title":"Nat Reviews Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis E","year":"2017","unstructured":"Lanitis E, Dangaj D, Irving M, Coukos G (2017) Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol 28:xii18\u2013xii32. 10.1093\/annonc\/mdx238","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce JA","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74\u201380. 10.1126\/science.aaa6204","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli E","year":"2019","unstructured":"Massarelli E, William W, Johnson F et al (2019) Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5:67\u201373. 10.1001\/jamaoncol.2018.4051","journal-title":"JAMA Oncol"},{"key":"ref17","first-page":"2248","article-title":"Glutathione S-Transferase P1 and NADPH Quinone Oxidoreductase Polymorphisms Are Associated with Aberrant Promoter Methylation of P16INK4a and O6-Methylguanine-DNA Methyltransferase in Sputum","volume":"62","author":"Gilliland FD","year":"2002","unstructured":"Gilliland FD, Harms HJ, Crowell RE, Li Y-F, Willink R, Belinsky SA (2002) Glutathione S-Transferase P1 and NADPH Quinone Oxidoreductase Polymorphisms Are Associated with Aberrant Promoter Methylation of P16INK4a and O6-Methylguanine-DNA Methyltransferase in Sputum. Cancer Res 62:2248\u20132252","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.Cir-18-0070","article-title":"Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs","volume":"6","author":"Christmas BJ","year":"2018","unstructured":"Christmas BJ, Rafie CI, Hopkins AC et al (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561\u20131577. 10.1158\/2326-6066.Cir-18-0070","journal-title":"Cancer Immunol Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"9463","DOI":"10.1128\/jvi.77.17.9463-9473.2003","article-title":"Identification of novel immunodominant CD4\u2009+\u2009Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity","volume":"77","author":"BenMohamed L","year":"2003","unstructured":"BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL, Nesburn AB (2003) Identification of novel immunodominant CD4\u2009+\u2009Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J Virol 77:9463\u20139473. 10.1128\/jvi.77.17.9463-9473.2003","journal-title":"J Virol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/jci138560","article-title":"Entinostat induces antitumor immune responses through immune editing of tumor neoantigens","volume":"131","author":"Truong AS","year":"2021","unstructured":"Truong AS, Zhou M, Krishnan B et al (2021) Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. J Clin Invest 131. 10.1172\/jci138560","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.Ccr-17-0741","article-title":"Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma","volume":"23","author":"Orillion A","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N et al (2017) Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res 23:5187\u20135201. 10.1158\/1078-0432.Ccr-17-0741","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu A","year":"2024","unstructured":"Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y (2024) Harnessing innate immune pathways for therapeutic advancement in cancer. Signal Transduct Target Therapy 9:68. 10.1038\/s41392-024-01765-9","journal-title":"Signal Transduct Target Therapy"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales L","year":"2015","unstructured":"Corrales L, Glickman LH, McWhirter SM et al (2015) Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep 11:1018\u20131030. 10.1016\/j.celrep.2015.04.031","journal-title":"Cell Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(sici)1096-9896(199909)189:1<12:","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers JM","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12\u201319. 10.1002\/(sici)1096-9896(199909)189:1%3C12::Aid-path431>3.0.Co;2-f","journal-title":"J Pathol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang A","year":"2016","unstructured":"Yang A, Farmer E, Wu TC, Hung CF (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75. 10.1186\/s12929-016-0293-9","journal-title":"J Biomed Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble CL","year":"2015","unstructured":"Trimble CL, Morrow MP, Kraynyak KA et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386:2078\u20132088. 10.1016\/S0140-6736(15)00239-1","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/s1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn JW","year":"2020","unstructured":"Youn JW, Hur SY, Woo JW et al (2020) Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol 21:1653\u20131660. 10.1016\/s1470-2045(20)30486-1","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S0264-410X(01)00406-6","article-title":"Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy","volume":"20","author":"Liu WJ","year":"2001","unstructured":"Liu WJ, Zhao K-N, Gao FG, Leggatt GR, Fernando GJP, Frazer IH (2001) Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20:862\u2013869. https:\/\/doi.org\/10.1016\/S0264-410X(01)00406-6","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1158\/1078-0432.Ccr-07-1880","article-title":"Induction of Tumor-Specific CD4\u2009+\u2009and CD8\u2009+\u2009T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine","volume":"14","author":"Welters MJP","year":"2008","unstructured":"Welters MJP, Kenter GG, Piersma SJ et al (2008) Induction of Tumor-Specific CD4\u2009+\u2009and CD8\u2009+\u2009T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Clin Cancer Res 14:178\u2013187. 10.1158\/1078-0432.Ccr-07-1880","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1016\/j.vaccine.2022.10.069","article-title":"A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model","volume":"40","author":"Qi W","year":"2022","unstructured":"Qi W, Qingfeng L, Jing Z et al (2022) A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model. Vaccine 40:7693\u20137702. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.069","journal-title":"Vaccine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4049\/jimmunol.2000191","article-title":"Exploiting Pre-Existing CD4(+) T Cell Help from Bacille Calmette-Gu\u00e9rin Vaccination to Improve Antiviral Antibody Responses","volume":"205","author":"Ng TW","year":"2020","unstructured":"Ng TW, Wirchnianski AS, Wec AZ et al (2020) Exploiting Pre-Existing CD4(+) T Cell Help from Bacille Calmette-Gu\u00e9rin Vaccination to Improve Antiviral Antibody Responses. J Immunol 205:425\u2013437. 10.4049\/jimmunol.2000191","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen DS","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. 10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/fon-2016-0526","article-title":"Entinostat: a promising treatment option for patients with advanced breast cancer","volume":"13","author":"Connolly RM","year":"2017","unstructured":"Connolly RM, Rudek MA, Piekarz R (2017) Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol 13:1137\u20131148. 10.2217\/fon-2016-0526","journal-title":"Future Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity","volume":"25","author":"Sivick KE","year":"2018","unstructured":"Sivick KE, Desbien AL, Glickman LH et al (2018) Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep 25:3074\u201385e5. 10.1016\/j.celrep.2018.11.047","journal-title":"Cell Rep"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9890379\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9890379\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:31:58Z","timestamp":1784223118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9890379\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":34,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9890379\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,7,16]]},"subtype":"preprint"}}